Sanuwave (OTC:SNWV) (Alpharetta,Ga.) will begin the process of submitting its data to the FDA for approval of its dermaPace device for treating diabetic foot ulcers (DFU) and it will not make any changes to the clinical trial evaluating the device after it had a "positive" meeting with the agency earlier this month, the company said during a call on Tuesday.
